Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The United States Patent and Trademark Office has issued a patent for Lorus Therapeutics' LOR-253, which covers composition of matter and methods of treating cancer.
Subscribe to our email newsletter
The patent was initially set to expire in May 2026 and latter was granted a patent term adjustment that extends the expiry date to February 2028, the company said.
The small molecule anticancer drug is in Phase I trial which will assess the safety profile and antitumor activity and will determine the recommended dose for subsequent Phase II trials.
Lorus president and CEO Aiping Young said: "Allowance of our US patent for LOR-253 is vital for the continued growth of Lorus, and is in line with our core IP strategy, which is to obtain exclusivity for LOR-253 in key markets."